Reneo Stock Analysis

RPHM -  USA Stock  

USD 10.44  1.81  20.97%

The big decline in price over the last few months for Reneo Pharmaceuticals created some momentum for stakeholders as it was traded today as low as 10.0 and as high as 10.64 per share. The company executives failed to add value to investors and positioning the company supply of money to exploit market volatility in May. However, diversifying your holdings with Reneo Pharmaceuticals or any similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 6.8. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Reneo Pharmaceuticals partners.
Additionally, take a look at Your Equity Center.

Search Stock Analysis 

The Reneo Pharmaceuticals stock analysis report makes it easy to digest most publicly released information about Reneo Pharmaceuticals and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Reneo stock analysis module also helps to analyze the Reneo Pharmaceuticals price relationship with some important fundamental indicators such as market cap and management efficiency.

Reneo Stock Analysis Notes

The company had not issued any dividends in recent years. Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. The company was incorporated in 2014 and is headquartered in San Diego, California. Reneo Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 12 people. To find out more about Reneo Pharmaceuticals contact the company at 858-283-0280 or learn more at

Reneo Pharmaceuticals Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Reneo Pharmaceuticals' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Reneo Pharmaceuticals or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Reneo Pharmaceuticals generates negative expected return over the last 90 days
Reneo Pharmaceuticals has high historical volatility and very poor performance
Reneo Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (19.46 M).
Latest headline from MacroaxisInsider: Purchase by Muralidhar Bali of 16605 shares of Reneo Pharmaceuticals

Reneo Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 289.8 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Reneo Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Reneo Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (30.27) % which means that it has lost $30.27 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (53.23) %, meaning that it created substantial loss on money invested by shareholders. Reneo Pharmaceuticals management efficiency ratios could be used to measure how well reneo pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 20th of June, Reneo Pharmaceuticals holds the risk adjusted performance of (0.07), and Coefficient Of Variation of (839.92). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Reneo Pharmaceuticals, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We have analyze and collected data for nineteen technical drivers for Reneo Pharmaceuticals, which can be compared to its competitors. Please check Reneo Pharmaceuticals variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Reneo Pharmaceuticals is priced some-what accurately, providing market reflects its current price of 10.44 per share. Given that Reneo Pharmaceuticals has jensen alpha of (0.81), we recommend you to check out Reneo Pharmaceuticals's recent market performance to make sure the company can sustain itself at a future point.

Reneo Pharmaceuticals Price Movement Analysis

The output start index for this execution was thirteen with a total number of output elements of thirty-nine. The Moving Average is predictive technique used to analyze Reneo Pharmaceuticals price data points by creating a series of averages of different subsets of Reneo Pharmaceuticals entire price series. View also all equity analysis or get more info about all moving average overlap studies indicator.

Reneo Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Reneo Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Reneo Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Reneo Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Reneo Pharmaceuticals Technical and Predictive Indicators

Reneo Pharmaceuticals Forecast Models

Reneo Pharmaceuticals time-series forecasting models is one of many Reneo Pharmaceuticals' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Reneo Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Reneo Pharmaceuticals Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Reneo Pharmaceuticals stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Reneo shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Reneo Pharmaceuticals. By using and applying Reneo Stock analysis, traders can create a robust methodology for identifying Reneo entry and exit points for their positions.
Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. The company was incorporated in 2014 and is headquartered in San Diego, California. Reneo Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 12 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Reneo Pharmaceuticals to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Companies Directory Now


Companies Directory

Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
All  Next Launch Module
Additionally, take a look at Your Equity Center. Note that the Reneo Pharmaceuticals information on this page should be used as a complementary analysis to other Reneo Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Complementary Tools for Reneo Pharmaceuticals Stock analysis

When running Reneo Pharmaceuticals price analysis, check to measure Reneo Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Reneo Pharmaceuticals is operating at the current time. Most of Reneo Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Reneo Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Reneo Pharmaceuticals' price. Additionally, you may evaluate how the addition of Reneo Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
ETF Directory
Find actively-traded Exchange Traded Funds (ETF) from around the world
CEO Directory
Screen CEOs from public companies around the world
Global Correlations
Find global opportunities by holding instruments from different markets
The market value of Reneo Pharmaceuticals is measured differently than its book value, which is the value of Reneo that is recorded on the company's balance sheet. Investors also form their own opinion of Reneo Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Reneo Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Reneo Pharmaceuticals' market value can be influenced by many factors that don't directly affect Reneo Pharmaceuticals underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Reneo Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Reneo Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Reneo Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.